CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.05
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Surface Oncology Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.05
Open* 1.02
1-Year Change* -21.54%
Day's Range* 0.99 - 1.05
52 wk Range 0.56-1.43
Average Volume (10 days) 466.36K
Average Volume (3 months) 16.51M
Market Cap 65.08M
P/E Ratio -100.00K
Shares Outstanding 60.82M
Revenue N/A
EPS -1.54
Dividend (Yield %) N/A
Beta 1.74
Next Earnings Date Oct 31, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 7, 2023 1.05 0.03 2.94% 1.02 1.05 0.99
Sep 6, 2023 1.05 0.07 7.14% 0.98 1.08 0.98
Sep 5, 2023 0.99 -0.06 -5.71% 1.05 1.05 0.98
Sep 1, 2023 1.06 0.02 1.92% 1.04 1.08 1.02
Aug 31, 2023 1.05 0.03 2.94% 1.02 1.06 1.01
Aug 30, 2023 1.04 0.02 1.96% 1.02 1.06 1.02
Aug 29, 2023 1.03 0.07 7.29% 0.96 1.04 0.96
Aug 28, 2023 0.98 0.03 3.16% 0.95 0.98 0.92
Aug 25, 2023 0.93 0.02 2.20% 0.91 0.93 0.91
Aug 24, 2023 0.93 0.02 2.20% 0.91 0.93 0.89
Aug 23, 2023 0.92 0.00 0.00% 0.92 0.96 0.92
Aug 22, 2023 0.89 -0.01 -1.11% 0.90 0.92 0.87
Aug 21, 2023 0.90 0.02 2.27% 0.88 0.92 0.87
Aug 18, 2023 0.88 0.05 6.02% 0.83 0.89 0.83
Aug 17, 2023 0.86 -0.02 -2.27% 0.88 0.89 0.85
Aug 16, 2023 0.88 -0.01 -1.12% 0.89 0.90 0.88
Aug 15, 2023 0.89 0.01 1.14% 0.88 0.89 0.86
Aug 14, 2023 0.88 -0.02 -2.22% 0.90 0.91 0.87
Aug 11, 2023 0.91 -0.01 -1.09% 0.92 0.92 0.90
Aug 10, 2023 0.92 0.02 2.22% 0.90 0.94 0.90

Surface Oncology Events

Time (UTC) Country Event
Thursday, March 7, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Surface Oncology Inc Earnings Release
Q4 2023 Surface Oncology Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 30 2.687 126.162 15.36 59.417
Revenue 30 2.687 126.162 15.36 59.417
Total Operating Expense 91.869 78.7 66.825 70.149 66.014
Selling/General/Admin. Expenses, Total 27.635 27.769 25.669 23.627 16.076
Research & Development 64.234 50.931 38.907 49.099 52.492
Interest Expense (Income) - Net Operating 2.249 -2.577 -2.554
Operating Income -61.869 -76.013 59.337 -54.789 -6.597
Net Income Before Taxes -63.586 -78.485 59.337 -54.789 -6.597
Net Income After Taxes -63.586 -78.485 59.337 -54.789 -6.597
Net Income Before Extra. Items -63.586 -78.485 59.337 -54.789 -6.597
Net Income -63.586 -78.485 59.337 -54.789 -6.597
Total Adjustments to Net Income 0 0 -0.011
Income Available to Common Excl. Extra. Items -63.586 -78.485 59.337 -54.789 -6.608
Income Available to Common Incl. Extra. Items -63.586 -78.485 59.337 -54.789 -6.608
Diluted Net Income -63.586 -78.485 59.337 -54.789 -6.608
Diluted Weighted Average Shares 55.7614 44.2433 38.1418 27.8549 19.9908
Diluted EPS Excluding Extraordinary Items -1.14032 -1.77394 1.5557 -1.96694 -0.33055
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -1.14032 -1.77394 1.5557 -1.96691 -0.32985
Interest Income (Expense), Net Non-Operating -3.146 -2.546
Other, Net 1.429 0.074
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Total Operating Expense 25.641 19.663 21.184 22.898 24.624
Selling/General/Admin. Expenses, Total 8.576 5.886 5.896 6.004 6.426
Research & Development 13.831 13.777 15.288 16.894 18.198
Operating Income -25.641 -19.663 -21.184 -22.898 -24.624
Interest Income (Expense), Net Non-Operating -3.108 -0.932 -0.902 -0.829 -0.733
Other, Net 0.557 0.854 0.754 0.487 0.144
Net Income Before Taxes -28.192 -19.741 -21.332 -23.24 -25.213
Net Income After Taxes -28.192 -19.741 -21.332 -23.24 -25.213
Net Income Before Extra. Items -28.192 -19.741 -21.332 -23.24 -25.213
Net Income -28.192 -19.741 -21.332 -23.24 -25.213
Income Available to Common Excl. Extra. Items -28.192 -19.741 -21.332 -23.24 -25.213
Income Available to Common Incl. Extra. Items -28.192 -19.741 -21.332 -23.24 -25.213
Diluted Net Income -28.192 -19.741 -21.332 -23.24 -25.213
Diluted Weighted Average Shares 60.7179 60.628 60.6154 59.0545 54.6548
Diluted EPS Excluding Extraordinary Items -0.46431 -0.32561 -0.35192 -0.39353 -0.46131
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.41105 -0.32561 -0.35192 -0.39353 -0.46131
Dilution Adjustment
Unusual Expense (Income) 3.234
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 129.14 157.346 180.509 107.926 164.601
Cash and Short Term Investments 124.823 154.149 175.141 105.161 158.835
Cash & Equivalents 50.91 56.045 175.141 46.755 82.912
Short Term Investments 73.913 98.104 0 58.406 75.923
Total Receivables, Net 0.197 0.765 2.571 0.336 1.246
Prepaid Expenses 4.12 2.432 2.797 2.429 4.52
Other Current Assets, Total 0
Total Assets 159.91 190.847 217.138 131.693 174.065
Property/Plant/Equipment, Total - Net 29.173 31.521 34.575 22.144 8.226
Property/Plant/Equipment, Total - Gross 38.29 39.274 40.759 26.658 10.959
Accumulated Depreciation, Total -9.117 -7.753 -6.184 -4.514 -2.733
Other Long Term Assets, Total 1.597 1.98 2.054 1.623 1.238
Total Current Liabilities 16.26 20.023 17.651 19.274 27.177
Accounts Payable 0.256 1.55 1.674 3.384 3.412
Accrued Expenses 13.858 15.235 14.929 10.22 8.263
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 2.146 3.238 1.048 5.67 15.502
Total Liabilities 66.507 71.947 61.391 75.027 71.203
Total Long Term Debt 25.585 25.015 14.759 5.109 0
Other Liabilities, Total 24.662 26.909 28.981 50.644 44.026
Total Equity 93.403 118.9 155.747 56.666 102.862
Redeemable Preferred Stock 0 0
Common Stock 0.006 0.005 0.004 0.003 0.003
Additional Paid-In Capital 298.741 259.859 218.001 178.155 169.784
Retained Earnings (Accumulated Deficit) -204.329 -140.743 -62.258 -121.595 -66.806
Other Equity, Total -1.015 -0.221 0 0.103 -0.119
Total Liabilities & Shareholders’ Equity 159.91 190.847 217.138 131.693 174.065
Total Common Shares Outstanding 60.579 46.9588 40.7071 27.8933 27.7726
Preferred Stock - Non Redeemable, Net 0 0 0
Long Term Debt 25.585 25.015 14.759 5.109
Accounts Receivable - Trade, Net 0 0.518 2.571
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 107.209 129.14 150.122 161.505 184.285
Cash and Short Term Investments 102.055 124.823 146.35 156.648 150.393
Cash & Equivalents 28.982 50.91 65.096 74.824 65.657
Short Term Investments 73.073 73.913 81.254 81.824 84.736
Prepaid Expenses 5.154 4.317 3.772 4.857 3.892
Total Assets 137.008 159.91 181.621 193.979 217.68
Property/Plant/Equipment, Total - Net 28.204 29.173 29.813 30.651 31.395
Other Long Term Assets, Total 1.595 1.597 1.686 1.823 2
Total Current Liabilities 14.75 16.26 17.992 19.725 19.561
Accounts Payable 1.108 0.256 0.535 0.486 2.625
Accrued Expenses 10.423 16.004 17.457 16.447 16.223
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 3.219 0 2.792 0.713
Total Liabilities 61.177 66.507 68.802 68.263 70.693
Total Long Term Debt 22.488 25.585 25.462 22.519 24.448
Long Term Debt 22.488 25.585 25.462 22.519 24.448
Other Liabilities, Total 23.939 24.662 25.348 26.019 26.684
Total Equity 75.831 93.403 112.819 125.716 146.987
Redeemable Preferred Stock
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.006 0.006 0.006 0.006 0.006
Additional Paid-In Capital 300.464 298.741 297.179 286.637 282.436
Retained Earnings (Accumulated Deficit) -224.07 -204.329 -182.997 -159.757 -134.544
Other Equity, Total -0.569 -1.015 -1.369 -1.17 -0.911
Total Liabilities & Shareholders’ Equity 137.008 159.91 181.621 193.979 217.68
Total Common Shares Outstanding 60.7169 60.579 60.5423 55.3849 54.3476
Total Receivables, Net 0 30
Accounts Receivable - Trade, Net 0 30
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -63.586 -78.485 59.337 -54.789 -6.597
Cash From Operating Activities -59.552 -62.344 29.997 -60.14 -13.222
Cash From Operating Activities 1.368 1.569 1.67 1.785 1.347
Non-Cash Items 10.254 12.463 11.319 7.116 4.854
Cash Taxes Paid 0 0 0.028
Changes in Working Capital -7.588 2.109 -42.329 -14.252 -12.826
Cash From Investing Activities 22.757 -99.252 58.307 16.965 -36.584
Capital Expenditures -0.497 -0.12 -0.043 -1.538 -2.019
Other Investing Cash Flow Items, Total 23.254 -99.132 58.35 18.503 -34.565
Cash From Financing Activities 31.66 42.5 40.082 7.415 110.376
Financing Cash Flow Items 0 9.469
Issuance (Retirement) of Stock, Net 31.66 31.813 30.082 0.279 100.907
Issuance (Retirement) of Debt, Net 0 10.687 10 7.136 0
Net Change in Cash -5.135 -119.096 128.386 -35.76 60.57
Cash Interest Paid 2.476 1.406 1.052
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -19.741 -63.586 -42.254 -19.014 6.199
Cash From Operating Activities -23.439 -59.552 -37.798 -18.971 -23.566
Cash From Operating Activities 0.318 1.368 1.037 0.691 0.345
Non-Cash Items 2.251 10.254 8.153 5.682 2.803
Cash Interest Paid 1.746 2.476 1.746 1.097 0.531
Changes in Working Capital -6.267 -7.588 -4.734 -6.33 -32.913
Cash From Investing Activities 1.434 22.757 15.232 14.909 12.465
Capital Expenditures -0.017 -0.497 -0.205 -0.146 -0.035
Other Investing Cash Flow Items, Total 1.451 23.254 15.437 15.055 12.5
Cash From Financing Activities 0.077 31.66 31.617 22.841 20.713
Issuance (Retirement) of Stock, Net 0.077 31.66 31.617 22.841 20.713
Issuance (Retirement) of Debt, Net 0
Net Change in Cash -21.928 -5.135 9.051 18.779 9.612

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Surface Oncology Company profile

About Surface Oncology Inc

Surface Oncology, Inc. is a clinical-stage, immuno-oncology company focused on developing antibody therapies focused on the tumor microenvironment. The Company is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Its pipeline includes two wholly owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a pre-clinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase I) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Surface Oncology Inc revenues decreased 98% to $2.7M. Net loss totaled $78.5M vs. income of $59.3M. Revenues reflect License-related revenue decrease of 97% to $2.7M, Collaboration revenue - related party decrease from $38.6M to $0K. Net loss reflects Research and development - Balancing increase of 34% to $48.5M (expense), Stock-based Compensation in SGA increase of 24% to $6.1M (expense).

Industry: Biotechnology & Medical Research (NEC)

50 Hampshire Street, 8Th Floor
02139

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

BTC/USD

43,836.50 Price
-0.520% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

16,080.90 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Gold

2,004.85 Price
-1.180% 1D Chg, %
Long position overnight fee -0.0198%
Short position overnight fee 0.0116%
Overnight fee time 22:00 (UTC)
Spread 0.50

Oil - Crude

71.41 Price
+2.320% 1D Chg, %
Long position overnight fee -0.0204%
Short position overnight fee -0.0015%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading